-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明，无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Janux Therapeutics (NASDAQ:JANX) Shares Gap Up to $12.76
Janux Therapeutics (NASDAQ:JANX) Shares Gap Up to $12.76
Janux Therapeutics, Inc. (NASDAQ:JANX – Get Rating)'s share price gapped up prior to trading on Monday . The stock had previously closed at $12.76, but opened at $13.08. Janux Therapeutics shares last traded at $12.60, with a volume of 106 shares.
Janux Therapeutics Stock Performance
The stock has a fifty day moving average of $13.36 and a 200 day moving average of $13.07. The company has a market capitalization of $533.29 million, a P/E ratio of -10.10 and a beta of 1.69.
Get Janux Therapeutics alerts:Janux Therapeutics (NASDAQ:JANX – Get Rating) last announced its earnings results on Tuesday, August 9th. The company reported ($0.41) EPS for the quarter, missing analysts' consensus estimates of ($0.37) by ($0.04). Janux Therapeutics had a negative return on equity of 15.10% and a negative net margin of 809.63%. The company had revenue of $2.37 million during the quarter. Research analysts anticipate that Janux Therapeutics, Inc. will post -1.74 EPS for the current fiscal year.
Institutional Investors Weigh In On Janux Therapeutics
A number of institutional investors have recently bought and sold shares of JANX. Amalgamated Bank purchased a new stake in Janux Therapeutics in the 1st quarter worth $28,000. Parkwood LLC increased its stake in Janux Therapeutics by 19.4% in the 2nd quarter. Parkwood LLC now owns 33,750 shares of the company's stock worth $34,000 after buying an additional 5,492 shares in the last quarter. American International Group Inc. increased its stake in Janux Therapeutics by 25.3% in the 1st quarter. American International Group Inc. now owns 8,813 shares of the company's stock worth $126,000 after buying an additional 1,782 shares in the last quarter. MetLife Investment Management LLC increased its stake in Janux Therapeutics by 100.2% in the 1st quarter. MetLife Investment Management LLC now owns 10,614 shares of the company's stock worth $152,000 after buying an additional 5,312 shares in the last quarter. Finally, New York State Common Retirement Fund increased its stake in Janux Therapeutics by 63.0% in the 1st quarter. New York State Common Retirement Fund now owns 15,521 shares of the company's stock worth $223,000 after buying an additional 6,000 shares in the last quarter. Hedge funds and other institutional investors own 69.40% of the company's stock.Janux Therapeutics Company Profile
(Get Rating)
Janux Therapeutics, Inc, a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2.
See Also
- Get a free copy of the StockNews.com research report on Janux Therapeutics (JANX)
- Still Lovin' It: Investors Keep Visiting McDonald's
- Did FedEx Just Deliver A Buying Opportunity?
- Autozone Shifts Back Into Rally-Mode, New Highs Are In Sight
- Upwork Shares Stumble into Bargain Territory
- Kroger's is Your One-Stop Consumer Staples Stock
Receive News & Ratings for Janux Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Janux Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
Janux Therapeutics, Inc. (NASDAQ:JANX – Get Rating)'s share price gapped up prior to trading on Monday . The stock had previously closed at $12.76, but opened at $13.08. Janux Therapeutics shares last traded at $12.60, with a volume of 106 shares.
JANUX治疗公司(纳斯达克代码：JANX-GET评级)的股价在周一交易前大幅上涨。该股此前收盘报12.76美元，但开盘报13.08美元。JANUX治疗公司的股票最后交易价格为12.60美元，成交量为106股。
Janux Therapeutics Stock Performance
Janux Treateutics股票表现
The stock has a fifty day moving average of $13.36 and a 200 day moving average of $13.07. The company has a market capitalization of $533.29 million, a P/E ratio of -10.10 and a beta of 1.69.
该股的50日移动均线为13.36美元，200日移动均线为13.07美元。该公司市值为5.3329亿美元，市盈率为-10.10，贝塔系数为1.69。
Janux Therapeutics (NASDAQ:JANX – Get Rating) last announced its earnings results on Tuesday, August 9th. The company reported ($0.41) EPS for the quarter, missing analysts' consensus estimates of ($0.37) by ($0.04). Janux Therapeutics had a negative return on equity of 15.10% and a negative net margin of 809.63%. The company had revenue of $2.37 million during the quarter. Research analysts anticipate that Janux Therapeutics, Inc. will post -1.74 EPS for the current fiscal year.
JANUX治疗公司(纳斯达克代码：JANX-GET评级)上一次公布收益结果是在8月9日星期二。该公司公布了该季度每股收益(0.41美元)，低于分析师普遍预期的(0.37美元)和(0.04美元)。雅诺治疗公司的净资产回报率为负15.10%，净利润率为负809.63%。该公司本季度的收入为237万美元。研究分析师预计，Janux治疗公司本会计年度的每股收益将达到1.74美元。
Institutional Investors Weigh In On Janux Therapeutics
机构投资者对Janux治疗公司的看法
Janux Therapeutics Company Profile
Janux治疗公司简介
(Get Rating)
(获取评级)
Janux Therapeutics, Inc, a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2.
Janux治疗公司是一家生物制药公司，开发基于专有的肿瘤激活T细胞激活器(TRACTr)平台技术的疗法，用于治疗癌症患者。该公司处于临床前或发现阶段的主要候选TRACTr产品针对前列腺特异性膜抗原、表皮生长因子受体和滋养层细胞表面抗原2。
See Also
另请参阅
- Get a free copy of the StockNews.com research report on Janux Therapeutics (JANX)
- Still Lovin' It: Investors Keep Visiting McDonald's
- Did FedEx Just Deliver A Buying Opportunity?
- Autozone Shifts Back Into Rally-Mode, New Highs Are In Sight
- Upwork Shares Stumble into Bargain Territory
- Kroger's is Your One-Stop Consumer Staples Stock
- 免费获取StockNews.com关于Janux治疗公司的研究报告(Janx)
- 仍然爱着它：投资者继续光顾麦当劳
- 联邦快递刚刚提供了一个买入机会吗？
- 自动区重新进入拉力赛模式，新高在望
- Upwork股价跌入便宜货领域
- 克罗格百货是你的一站式消费者史泰博股票
Receive News & Ratings for Janux Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Janux Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
获得Janux治疗日报的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对Janux治疗公司和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能，分享给你的好友吧